Table 2: Clinicopathological profile of patients.
|
Frequency |
Percent |
Valid Percent |
Cumulative Percent |
|
CD10 |
Positive |
17 |
63.0 |
63.0 |
63.0 |
Negative |
10 |
37.0 |
37.0 |
100.0 |
|
Total |
27 |
100.0 |
100.0 |
|
|
BCL2 |
Positive |
22 |
81.5 |
81.5 |
81.5 |
Negative |
5 |
18.5 |
18.5 |
100.0 |
|
Total |
27 |
100.0 |
100.0 |
|
|
BCL6 |
Positive |
17 |
63.0 |
63.0 |
63.0 |
Negative |
10 |
37.0 |
37.0 |
100.0 |
|
Total |
27 |
100.0 |
100.0 |
|
|
MUM1 |
Positive |
12 |
44.4 |
44.4 |
44.4 |
Negative |
15 |
55.6 |
55.6 |
100.0 |
|
Total |
27 |
100.0 |
100.0 |
|
|
Ki67 |
≤20% |
14 |
51.9 |
51.9 |
51.9 |
21%=40% |
6 |
22.2 |
22.2 |
74.1 |
|
41%=60% |
4 |
14.8 |
14.8 |
88.9 |
|
>60% |
3 |
11.1 |
11.1 |
100.0 |
|
Total |
27 |
100.0 |
100.0 |
|
|
FLIPI |
Low |
1 |
3.7 |
3.7 |
3.7 |
Intermediate |
8 |
29.6 |
29.6 |
33.3 |
|
High |
18 |
66.7 |
66.7 |
100.0 |
|
Total |
27 |
100.0 |
100.0 |
|
|
Ann Arbor Stage |
IIB |
1 |
3.7 |
3.7 |
3.7 |
IIIA |
1 |
3.7 |
3.7 |
7.4 |
|
IIIB |
18 |
66.7 |
66.7 |
74.1 |
|
IVB |
7 |
25.9 |
25.9 |
100.0 |
|
Total |
27 |
100.0 |
100.0 |
|
|
Bone Marrow Involvement |
No |
22 |
81.5 |
81.5 |
81.5 |
Yes |
5 |
18.5 |
18.5 |
100.0 |
|
Total |
27 |
100.0 |
100.0 |
|
|
Hepatosplenomegaly |
No |
20 |
74.1 |
74.1 |
74.1 |
Yes |
7 |
25.9 |
25.9 |
100.0 |
|
Total |
27 |
100.0 |
100.0 |
|
|
B Syndrome |
Yes |
26 |
96.3 |
96.3 |
96.3 |
No |
1 |
3.7 |
3.7 |
100.0 |
|
Total |
27 |
100.0 |
100.0 |
|
|
High Tumor Burden |
Yes |
27 |
100.0 |
100.0 |
100.0 |